Prostate Cancer Support Group - Richmond, Va

Meeting Dates - 3rd Thurs. each month - Time 7:00 PM - No July Meeting - The Dec. date will vary - Call for details - Peter C. Moon Phd. at 804-346-4407 between 7 - 11:00 PM - Location - Ridge Baptist Church, 1515 Eastridge Road Richmond, VA 23229

Rva Prostate Cancer Support Group

For details Contact - Peter C. Moon Phd. at 804-346-4407 between 7 - 11:00 PM
Location - Ridge Baptist Church, 1515 Eastridge Road Richmond, VA 23229
Meetings are in the fellowship hall Bldg - at the back of the parking lot.

In good faith, this website was created to furnish you with helpful information. Nevertheless, no one who contributes or posts information to this website makes any guarantee regarding the information provided. Any decisions that you make regarding your health should be made in consultation with a qualified healthcare provider.

Affiliated with Us-TOO International Prostate Cancer Education & Support Network
Us Too International Other Support Groups Facts and Stats Emerging Treatments Articles Articles Bipolar Androgen Therapy Videos Links Complementary
Alternative Treatment Sources
Clinical Trials Advanced Prostate Cancer ADT Active Surveillance Prostate Cancer Detection Peter's Notes Herbs and
Alternative Treatments
Women Spouse Partner Page Past Meeting Page African Americans Page Flyer

Us Too Warriors,

Meeting - Jun, 2021

The Church Is Not Allowing Any Meetings Because of Covid-19.

Our Next Meeting Topic and Date are:

To Be Determined

Please bring your ideas - All are welcome.
Meeting Location - Ridge Baptist Church, 1515 Eastridge Road Richmond, VA 23229

Meetings are held in the fellowship hall Bldg - at the back of the parking lot
For more details Contact - Peter C. Moon Phd. at 804-346-4407 between 7 - 11:00 PM
Virtual Prostate Cancer Patient Festival-The National Prostate Cancer Conference Online
with presentations.

Various Dates and Times

Prostate Cancer Patient Conferences - A Festival Of Prostate Cancer Care - Free

Click on the Link below to For More Information.

Link: Festival


Us Too Warriors,

Please see that Foundation 1 Liquid blood test for Somatic mutations has been FDA approved for medicare for about 300+ mutations and can be used more than once if the cancer progresses. Foundation One will be doing a virtual presentation for our Sept 17 RVA Us Too meeting. I will be sending more information about how to sign on line when they send it to me.

Click on the Link below for the Foundation 1 Liquid Blood Test.

Link: Blood Test


Click on the Link below for the Latest Prostatepedia.

Link: Prostatepedia 21 20 Prostatepedia_V6_1_PRINTABLE.pdf


Us Too warriors, I hope you will take part in the Meeting and fund raising to keep the work of Our Us Too international going in these trying times.

SEA Blue 2021 is On! In Person! In Lincoln Park!

In Chicago! And Online! On September 26th!

We are very excited to announce that the 2021 SEA Blue Chicago Prostate Cancer Walk and Run is on! We are happy we will be able to finally see everyone's lovely faces again in person this September 26th in Lincoln Park. Be sure to mark your calendars! More information will be coming to you soon, so watch your email.

We together have been able to contribute about $3000 dollars for the last few years. It would be good if you can contribute what you can. I hope this will be a good year for you.
Sept 26, 2021 – Sept 26, 2021
Best Peter

See the Link below to view photos from past years of SEA Blue..

Link: SeaBlue
or Go To



Us Too Warriors,

This test is for men with advanced cancer with a rising PSA or CRPC or metastasis. These conditions should make it approvable by insurance if you have a tissue biopsy. If no biopsy, you will have to see what you can negotiate a for blood liquid biopsy test cost with the company. However, the liquid test is being submitted for FDA approval which may come through this year?? So Before you read all the details see if applies to your cancer situation

Websites follow for you to GOOGLE - see the link below

To see More - Click on the Link:

Link: Metastasis
or Go To 19 20 advanced cancer with rising PSA or CRPC.pdf


Flu Like Symptoms

RVA - Us Too Warriors:

If you have not gotten a flu shot this winter

If you have not gotten a flu shot this winter, please do before coming to our next meeting on March 19, 2020. The flu is still strong in Va. and most of the people in Virginia checked for Cov-19 have had the Flu!! Also, let's switch to elbow bumps instead of handshakes to prevent spread. We do not need to sit next to each other in the meeting's chairs- Think you are in grade school and the person next to you has the cooties.

Please do not come to the meetings if you are sick with a cold or flu like symptoms.

Below is an advertisement From Swanson for supplements that help with respiratory breathing to counter the Virus. I am presently taking 6 of them for PCa as follows:

Astragalus, Quercetin, Bromelain, Feverfew, Oregano, and Coleus Forskohlii

To Read the Article - Click on the Link:

Link: Swanson
or Go To


Prostate Cancer Research Institute - Prostate Cancer Program on March 28th for Free

RVA - Us Too Warriors:


It is going online because of the CoV-19 virus in California. Please take advantage of this Opportunity to gain Info in your fight.

Learn More About Advanced Prostate Cancer Treatments, Sbrt, Radiation, Genetic Testing, And More

To Read the Article - Click on the Link:

or Go To


Antiandrogens may increase mortality risk in men with CVD
Badar M. Mian, MD
August 30, 2019 - Volume: 47 - Issue: 9

Genitourinary Cancers, Prostate Cancer

Badar M. Mian, MDAdvanced prostate cancer and cardiovascular disease often coexist in older men. Over the last 5 years, new second-generation antiandrogens, namely abiraterone (ZYTIGA) and enzalutamide (XTANDI), are being used with more frequency in men with advanced prostate cancer. Patients with significant cardiovascular disease (CVD) are often excluded from clinical trials for reasons that are understandable. But in clinical practice, the excluded patients are often the ones treated with those same medications.

A new study suggests that newer antiandrogens may increase the risk of early mortality and hospitalization, especially in men with known CVD such as myocardial infarction, atrial fibrillation, congestive heart failure, stroke, or ischemic heart disease (Eur Urol Aug. 2, 2019 [Epub ahead of print]).

Lu-Yao and colleagues used the Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked files (representing nearly 31% of the U.S. population) to identify men with prostate cancer who had received chemotherapy and abiraterone or enzalutamide. A total of 3,876 patients were eligible for the study, including 2,845 treated with abiraterone and 1,031 treated with enzalutamide. The main goal of the analysis was to determine the mortality rate within 6 months after starting therapy with these two antiandrogens. They also wished to determine the risk of hospitalization after the initiation of antiandrogen therapy.

Also from Dr. Mian: Untreated MIBC has short natural course, significant morbidity

Interestingly, 67% of the eligible patients had one or more documented CVD before receiving abiraterone or enzalutamide.

In the post-chemotherapy group of patients being treated with abiraterone, 24% died within 6 months, compared with 17% in the pivotal trial that led to its approval. Among patients being treated with enzalutamide, 28% died within 6 months, compared with 12% in the pivotal trial. In the group without chemotherapy, 18% of patients died within 6 months of starting abiraterone and 17% died within 6 months of starting enzalutamide.

In the post-chemotherapy cohort receiving either abiraterone or enzalutamide, there was no significant difference in hospitalization rates between the two drugs. However, those with one or two CVDs had a 43% increased risk of hospitalization compared to those with no CVDs.

Next: Higher hospitalization rate in abi patients with no chemo

Antiandrogens may increase mortality risk in men with CVD: Page 2 of 2
Badar M. Mian, MD

August 30, 2019 - Volume: 47 - Issue: 9

Genitourinary Cancers, Prostate Cancer

Higher hospitalization rate in abi patients with no chemo

In the group without chemotherapy, abiraterone was associated with a higher rate of hospitalization than enzalutamide among patients with one or more CVDs. In this group, hospitalization rate was higher with abiraterone use even in the patients with no history of CVD.

As stated by the authors, the worse outcomes (cardiovascular toxicity and/or mortality) following the use of abiraterone have been reported by previously published meta-analyses. In the STAMPEDE trial, the addition of abiraterone was associated with improved cancer-free-survival but no real improvement in overall survival, likely due to increased cardiovascular mortality.

It appears that abiraterone is associated with worse outcomes even if there is no documented chemotherapy or CVDs. However, without direct comparison, we cannot suggest that one drug is superior to the other. Other antiandrogens such as apalutamide (Erleada) and darolutamide (Nubeqa) have been approved recently and the use of antiandrogens has been moving “upfront;” eg, before chemotherapy and without metastases. This will likely result in increased use of drugs in this class, making the issue of adverse outcomes even more relevant.

Read: Renal mass biopsy safe, but when is it necessary?

The usual limitations of a retrospective analysis apply to this study as well. The data do not allow for a comparison with an appropriate control group that did not receive abiraterone or enzalutamide, or direct comparison. However, the Medicare-linked SEER data represent a broad cross-section of the population that is afflicted with prostate cancer and CVDs, which makes the information presented here quite pertinent for most clinicians.

The phenomenon of worse outcomes in the real-world setting after the initial approval of a drug or device has been well documented. Clinicians often loosen the criteria beyond what was allowed in the clinical trials, exposing the patients to a host of drug-drug or drug-disease interactions.

The subjects of this study had also received androgen deprivation therapy, which is associated with developing CVDs. Is it possible that these subjects were primed, through previous use of ADT, for worse outcomes following the addition of abiraterone and enzalutamide? The unique contribution of these second-generation antiandrogens to cardiovascular mortality is not entirely clear.

Several professional organizations are offering workshops geared towards incorporating these and other oral anti-cancer agents into the practice of urology. Hopefully, the educational activities will sufficiently emphasize a more careful selection of patients for these drugs. There is a clear impetus for a multidisciplinary program to monitor the treatment and adverse outcomes of newer antiandrogens which, at present, may be out of the comfort zone of many urologists.
Us Too Warriors,
Dr Wallace who is behind these efforts is trying to shape this process to the needs of men with PCa. It may take about five minutes of your time if you can do it. Dr Wallace has been kind enough to speak to our group several times on radiation and seeds treatments for PCa.

Take my survey:

I hope you respond by expressing what you think of these online efforts to meet your needs that will help..


Click on Our Link

Link: Survey
or Go To


Project Healing Waters Fly Fishing
REEL RECOVERY is a national non-profit organization that conducts free fly-fishing retreats for men recovering from cancer. Go to the link below for the details & application Information.

Location - Graves Mountain Lodge & Rose River Farm in Syria, VA

For more information, contact Reel Recovery at: or call 800-699-4490
Website -

Click on Our Link to get the Project Healing Waters Application
Project Healing
Project Healing
or Go To
Us Too warriors,
Go to the website below to sign up for Bicalutamide and Metformin treatment for recurrent Prostate cancer and to see the requirements to qualify.
All the Best Peter

Click on Our Link

Link: Sign UP
or Go To

See below if you have not been treated and/or on active surveillance and your cancer is limited and local.

This issue of Prostatepedia is devoted to focal therapies. Interest in focal therapy is fueled by the promise of cancer control with fewer side effects than are seen after radiation or radical prostatectomy. From the patient perspective, this is certainly an attractive option. As a result, we have seen the development of an increasing list of approaches to focal therapy.

Click on Our Link to Read more
Not Treated
or Go To
Us Too Warriors,

At our Feb 2019 Meeting we had an Informative Program on ED from
"Peak Performance For Men".
This is A New, Proven and Successful Treatment for Erectile Dysfunction.

Focused Linear Compression Therapy (FLCT) protocol is scientifically proven to increase blood flow to the penis and optimize erections, sensitivity, and sexual performance. FLCT is a series of short comfortable treatments to the penis using focused linear compression sound waves that create long lasting results for erectile dysfunction and Peyronie's Disease by increasing blood flow and nerve tissue. The sound waves repair aged blood vessels, stimulate growth of new blood vessels and remove decades of micro-plaque. This procedure opens the blood vessels in the penis which is essential for a firm, rigid erection which also stimulates the nerve endings to greatly enhance sensitivity. This procedure is non-invasive, completely pain free with no side effects, no surgery, no use of drugs and no downtime. This breakthrough revolutionary technology is the only viable option for men with erectile dysfunction or men looking for better sexual performance with long-lasting results and no harmful side effects whatsoever.

Click on Our Links

Link: Freq Ask Questions

Link: Website
or Go To

Freq Ask Questions - Performance001.pdf
Website -

Us Too Warriors,

Please find below more Clinical trial information on the effectiveness
of SBRT treatments for PCa. This is a follow up on the information from September's
meeting by Dr. Cuttino.

All the Best,

Per the Requests for the Power Point Presentation
"The September 20th meeting"

Dr. Lauri Cuttino, VCUHS Assoc. Prof. of Radiation Oncology at VCUHS and the Medical Director of Radiation Oncology at the Sarah Cannon Cancer Center at Henrico Doctors' Hospital, who discussed Stereotactic Ablative Radiotherapy for Prostate Cancer and gave a Power Point Presentation: Treatment of Primary and Limited Metastases.

To Read the Power Point Presentation in PDF format
Click on Our Link

Link: PDF
or Go To SABR no video 92318.pdf


More Clinical trial information on the effectiveness of SBRT treatments

To Read the Clinical trial information
Click on Our Link

Link: SBRT
or Go To Phase 2 Multicenter Trial of Heterogeneous.pdf


RVa Us Too Warriors, If you are on social media,
You can spread awareness of PCa by adding the posts on the link below to your Social pages.

This is a long list of social media posts which you can use on your FACEBOOK pages for September which is Prostate Cancer Awareness month.

Just cut and paste onto your page! (ONE at a time)

If you do one every few days - this will really help to get the awareness out there!

Please let me know if you are going to participate. We can really make a huge impact here
if we all take a minute to post at least a few times this month.
Email - Terri Likowski

Click on Our Link
Link: Post
or Go To Posts for September 2018.pdf
Hampton University Proton Therapy Institute
HUPTI - 40 Enterprise Parkway - Hampton, VA 23666 - Phone - 877.251.6838

Proton therapy is a cancer treatment option most commonly used for localized cancer, meaning it may treat cancer that has not spread to other parts of the body. Though popularly used for prostate and breast cancers, it has become a standard form of care for numerous cancer types. Many patients, both young and old, have utilized proton therapy as an effective cancer treatment option.

Click on Our Link to visit their Website

or Go To

Click on Our Link to see their latest TV Spot

Link: TV Spot
or Go To
Us Too International - Hot Sheet 2019

Our monthly newsletter, the Hot SHEET, highlights the latest in treatment strategies as well as emerging treatments. The Hot SHEET is distributed free at chapter support group meetings, and is available in PDF on the Us TOO web site.

This is also a request for financial support to Us Too International Prostate Cancer Support.
Website of 2019 "Us Too Hotsheet News Letter"

To Read The Hot Sheet - Click on Our Link
Hot Sheet
or go to:

We are pleased to announce the first Us TOO support group call
for the women behind the men affected by prostate cancer.

Because prostate cancer is a couple's disease, the woman is often subject to her own concerns in addition to those she shares with her partner. A Forum for Her will be a regular call series which will focus on women and offer peer-to-peer support to address these concerns.

A Forum for Her is a regular call series (and invite-only Facebook group) which focuses on women and offers important peer-to-peer support. So far, the calls have been going great and will continue to expand.

As group membership grows and we become more comfortable with each other, we will be looking for volunteers to lead smaller group calls. If you would like to volunteer to help lead a small group call, please email me at or call 877-978-7866.

(Your involvement would not require too much time or effort beyond the typical call length of about an hour. We would only be looking for you to lead calls, not come up with information, materials, or topics.)

In order to address very specific experiences, these calls are open only to wives and female partners of men affected by prostate cancer.

Please note that space is limited - Contact me at or 877-978-7866 to reserve your spot and to get the call-in information!
Terri Likowski - Program Director/Support Group Services
Us TOO International - Prostate Cancer Education and Support Network
2720 S. River Road, Suite 112 - Des Plaines, IL 60018
877-978-7866 -
15th Annual Chicago
S.E.A. Blue Prostate Cancer Walk/Run
(Sept 15, 2019)

In the past our own Jerry Dean has participated in this event.

A personal update first. The good news is that this year marks 20 years that I have survived this relentless disease of prostate cancer. Last summer I underwent Cyberknife treatment. My PSA dropped with each subsequent measurement for several months until June of this year when it spiked again. And then after confirming it was not a lab measurement anomaly we began the process of trying to find out where it is in my body. My doctor in New York is part of a cutting edge clinical trial for imaging so we remain optimistic that we will be able to locate and treat it somehow, some way.

But lying between the realization that the fight is back on and the place of becoming truly optimistic about what comes next is a rickety bridge back into the wilderness experience of vulnerability and disappointment that we have been forced to visit many times before. I have been more emotional than usual this summer.

Whether they are tears of sadness or tears of joy is not always clear to me. There is so much to be joyful about. I have a new lens where a cataract once was. I have a new right knee and a new granddaughter. And I have and a published book (Lost But Not Forgotten) So the year that Cyberknife treatment bought me has been very fulfilling. And the future holds much promise for opportunities to live love and help impact the lives of others who are being thrust into the wilderness experiences of life.

One of the most rewarding things I do is volunteer with Us Too International. This organization sponsors over 200 support groups around the world. When I hear the stories about how men and their loved ones are being educated and given hope by those of us who have the lived experience with this disease it thrills my heart.

I know it’s not hard for most of you reading this to imagine what a relief it is to find someone in the wilderness who says to you. “Follow me I know how to get you through this experience of vulnerability and fear.” Because if we live long enough we all learn that the wilderness experiences of life are much closer than we think and we can be thrust into these disturbing places in a heartbeat.

So whatever our trial or tragedy we need wilderness walkers in our life. People who show up unexpectedly to point the way and say to us with confidence “If I can find my way through a mess like this then you can too.”

That is the essence of Us Too and why I am asking you to support me in September for the Sea Blue Walk in Chicago. I will not be walking this year due to the need to recuperate from knee surgery and a detached retina but I ask you to contribute nonetheless.

Thank you in advance for any contribution you are able to make.

If you wish to go, donate directly or register:

(Go To) (enter code POSTCARD2 for a $10.00 Discount)
or use the link - S.E.A. Blue Prostate Cancer Walk/Run

Click here to go to Jerry's fundraising page:
Jerry Deans
or Go To
The US Too "Hot Sheet"
The Hot SHEET highlights the latest in treatment strategies.

The monthly newsletter, the Hot Sheet, highlights the latest in treatment strategies as well as emerging treatments. The Hot SHEET is distributed free at chapter support group meetings, and is available in PDF on the Us TOO web site.

To Read The Hot Sheet - Click on Our Link
Hot Sheet
or go to:
Prostate Cancer Drugs

On this webpage you will find information and links for all available prostate cancer drugs, including:
androgen deprivation, chemotherapy, hormone therapy, immunotherapy and palliatives for advanced
prostate cancer. The drugs can take many forms including oral, intravenous, injection, and implant.
We have done our best to compile the latest information, but be sure to consult with your doctor before
entering into any drug program. If you see anything missing or information in need of updating
please email -

To Read and print this Handout - Click on Our Link


or go to

Life Extension Magazine

How to Reverse Markers of Prostate Cancer.

Despite prostate cancer being the second leading cause of cancer death in men, a raging debate has ensued as
to whether men should have annual PSA blood tests. The scales are tilting in favor of Life Extension®’s
multi-decade campaign to educate men about the importance of regular PSA screening. Not only are there proven
ways to reverse rising PSA levels, but breakthrough treatments can enable safer diagnosis and curative treatment
without the side effects associated with conventional surgery and radiation.

To Read The Articles - Click on Our Link

Life Extension Magazine

or go to:

website counter